Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
6
46%
Ph phase_2
7
54%

Phase Distribution

6

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
7(53.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(10)
Terminated(1)
Other(2)

Detailed Status

Completed10
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
90.9%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (46.2%)
Phase 27 (53.8%)

Trials by Status

completed1077%
terminated18%
unknown215%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

NCT00710333
completedphase_2

Juvista (Avotermin) in Scars Following Varicose Vein Removal

NCT00430326
completedphase_2

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

NCT00984503
completedphase_1

Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects

NCT00984581
completedphase_1

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

NCT00978367
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00710333Phase 1

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

Completed
NCT00430326Phase 2

Juvista (Avotermin) in Scars Following Varicose Vein Removal

Completed
NCT00984503Phase 2

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

Completed
NCT00984581Phase 1

Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects

Completed
NCT00978367Phase 1

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

Completed
NCT00978302Phase 1

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

Completed
NCT00469235Phase 1

Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars

Completed
NCT00847795Phase 1

Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.

Completed
NCT00432211Phase 2

Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.

Unknown
NCT00432328Phase 2

Juvista (Avotermin) in Breast Reduction Surgery Scars

Terminated
NCT00436449Phase 2

RN1001(Avotermin) in Scar Improvement Following Breast Augmentation

Completed
NCT00656227Phase 2

A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision

Unknown
NCT00627536Phase 2

Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13